Category Business

VantAI Unveils Neo-1, the First AI Model for

VantAI Unveils Neo-1, the First AI Model for Rewiring Molecular Interactions in Therapeutic Design

VantAI Unveils Neo-1: A Groundbreaking AI Model for Revolutionary Drug Design VantAI, a cutting-edge biotechnology company, has unveiled Neo-1, a pioneering AI model that is set to transform the future of drug development. Announced at the NVIDIA GTC 2025 conference,…

Read MoreVantAI Unveils Neo-1, the First AI Model for Rewiring Molecular Interactions in Therapeutic Design
IQVIA Launches Site Lab Navigator with e-Requisition Innovation for Clinical Trials

IQVIA Launches Site Lab Navigator with e-Requisition Innovation for Clinical Trials

IQVIA Laboratories Launches Site Lab Navigator to Transform Clinical Trials with e-Requisition Innovation IQVIA Laboratories, a global leader in drug discovery and development laboratory services, has unveiled its Site Lab Navigator — an advanced suite of solutions designed to automate…

Read MoreIQVIA Launches Site Lab Navigator with e-Requisition Innovation for Clinical Trials

San Francisco Equity Partners Buys Formula Corp, a Top Cleaning Products Developer for Consumers and Professionals

San Francisco Equity Partners Acquires Formula Corp, a Leader in Sustainable Cleaning Products Manufacturing In a strategic move to expand its portfolio of specialty manufacturing businesses, San Francisco Equity Partners (SFEP) has announced the acquisition of a majority stake in…

Read MoreSan Francisco Equity Partners Buys Formula Corp, a Top Cleaning Products Developer for Consumers and Professionals

ESAB Corporation Reports Q4 2024 Results and Provides Full-Year 2025 Guidance

ESAB Corporation Reports Strong Q4 2024 Results, Provides Full-Year 2025 Guidance and Strategic Growth Updates ESAB Corporation (NYSE: ESAB), a premier industrial compounder and global leader in welding and cutting solutions, has announced its financial results for the fourth quarter…

Read MoreESAB Corporation Reports Q4 2024 Results and Provides Full-Year 2025 Guidance